Compare MYFW & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MYFW | NKTX |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 256.7M | 247.4M |
| IPO Year | 2018 | 2020 |
| Metric | MYFW | NKTX |
|---|---|---|
| Price | $27.64 | $2.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $26.50 | $11.33 |
| AVG Volume (30 Days) | 20.7K | ★ 948.3K |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.02 | 11.88 |
| EPS | ★ 1.34 | N/A |
| Revenue | ★ $96,914,000.00 | N/A |
| Revenue This Year | $20.48 | N/A |
| Revenue Next Year | $9.70 | N/A |
| P/E Ratio | $20.84 | ★ N/A |
| Revenue Growth | ★ 7.60 | N/A |
| 52 Week Low | $20.10 | $1.63 |
| 52 Week High | $28.00 | $3.65 |
| Indicator | MYFW | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 62.81 | 51.17 |
| Support Level | $22.04 | $1.88 |
| Resistance Level | $28.00 | $3.65 |
| Average True Range (ATR) | 0.67 | 0.27 |
| MACD | 0.13 | -0.01 |
| Stochastic Oscillator | 77.12 | 36.51 |
First Western Financial Inc is a financial holding company that provides a fully integrated suite of wealth management services on its private trust bank platform, which includes a comprehensive selection of deposit, loan, trust, wealth planning, and investment management products and services. The company has two operating segments; The Wealth Management segment consists of operations relative to the Company's fully integrated wealth management products and services, and The Mortgage segment consists of operations relative to the Company's residential mortgage service offerings. The bank derives its majority revenue from the wealth management segment.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.